VIP

Summary

Gene Symbol: VIP
Description: vasoactive intestinal peptide
Alias: PHM27, VIP peptides, prepro-VIP
Species: human

Top Publications

  1. ncbi A VIP hybrid antagonist: from developmental neurobiology to clinical applications
    I Gozes
    Department of Clinical Biochemistry, Tel Aviv University, Israel
    Cell Mol Neurobiol 15:675-87. 1995
  2. ncbi Combination chemotherapy with vinblastine, ifosfamide and cisplatin in bulky seminoma
    C Clemm
    Department of Internal Medicine III, University of Munich, West Germany
    Acta Oncol 28:231-5. 1989
  3. pmc The mechanisms of the relaxation induced by vasoactive intestinal peptide in the porcine coronary artery
    J Kawasaki
    Division of Molecular Cardiology, Faculty of Medicine, Kyushu University, Fukuoka, Japan
    Br J Pharmacol 121:977-85. 1997
  4. ncbi [Evaluation of commercial kits for a rapid detection of Escherichia coli O157 in stool]
    T Tsukamoto
    Osaka Prefectural Institute of Public Health
    Kansenshogaku Zasshi 72:40-4. 1998
  5. ncbi Active immunization with vasoactive intestinal peptide in turkey hens
    M E El-Halawani
    Department of Animal Science, University of Minnesota, Saint Paul 55108, USA
    Poult Sci 79:349-54. 2000
  6. ncbi Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells
    Ana Valdehita
    Molecular Neuroendocrinology Unit, Department of Biochemistry and Molecular Biology, Alcala University, Alcala de Henares 28871, Spain
    Regul Pept 144:101-8. 2007
  7. ncbi The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics
    Emilie Ceraudo
    Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de recherche Biomedicale Bichat Beaujon, CRB3, Faculte de Medecine Xavier Bichat, 75018, Paris, France
    Mol Endocrinol 22:147-55. 2008
  8. ncbi Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells
    Beatriz Collado
    Molecular Neuroendocrinology Unit, Department of Biochemistry and Molecular Biology, Alcala University, E 28871 Alcala de Henares, Spain
    Regul Pept 119:69-75. 2004
  9. doi Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer
    Ana Valdehita
    Molecular Neuroendocrinology Unit, Department of Biochemistry and Molecular Biology, Alcala University, 28871 Alcala de Henares, Spain
    Peptides 31:2035-45. 2010
  10. ncbi VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death
    D E Brenneman
    Section on Developmental and Molecular Pharmacology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Brain Res 838:27-36. 1999

Detail Information

Publications219 found, 100 shown here

  1. ncbi A VIP hybrid antagonist: from developmental neurobiology to clinical applications
    I Gozes
    Department of Clinical Biochemistry, Tel Aviv University, Israel
    Cell Mol Neurobiol 15:675-87. 1995
    1. The 28 amino acid vasoactive intestinal peptide, VIP, was originally isolated from the intestine, following a bioassay measuring vasodilating properties...
  2. ncbi Combination chemotherapy with vinblastine, ifosfamide and cisplatin in bulky seminoma
    C Clemm
    Department of Internal Medicine III, University of Munich, West Germany
    Acta Oncol 28:231-5. 1989
    Since 1982, 24 patients with bulky seminoma were treated with the VIP-regimen consisting of vinblastine 6 mg/m2 days 1+2, ifosfamide 1.5 g/m2 days 1-5, cisplatin 20 mg/m2 days 1-5...
  3. pmc The mechanisms of the relaxation induced by vasoactive intestinal peptide in the porcine coronary artery
    J Kawasaki
    Division of Molecular Cardiology, Faculty of Medicine, Kyushu University, Fukuoka, Japan
    Br J Pharmacol 121:977-85. 1997
    1. This study was designed to investigate the mechanism of the relaxation induced by vasoactive intestinal peptide (VIP) in medial strips of the porcine coronary artery, by determining the effect on the cytosolic Ca2+ concentration ([Ca2+..
  4. ncbi [Evaluation of commercial kits for a rapid detection of Escherichia coli O157 in stool]
    T Tsukamoto
    Osaka Prefectural Institute of Public Health
    Kansenshogaku Zasshi 72:40-4. 1998
    ..coli O157 were compared. VIP, Reveal, Path Stik, Quix, Now EH and EZ coli were found to detect E. coli O157 greater than 10(6) CFU/ml...
  5. ncbi Active immunization with vasoactive intestinal peptide in turkey hens
    M E El-Halawani
    Department of Animal Science, University of Minnesota, Saint Paul 55108, USA
    Poult Sci 79:349-54. 2000
    Active immunization of turkey hens against vasoactive intestinal peptide (VIP) has been shown to inhibit incubation behavior and to increase egg production in second-cycle hens...
  6. ncbi Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells
    Ana Valdehita
    Molecular Neuroendocrinology Unit, Department of Biochemistry and Molecular Biology, Alcala University, Alcala de Henares 28871, Spain
    Regul Pept 144:101-8. 2007
    Previous studies have shown that vasoactive intestinal peptide (VIP) and its receptors (VPAC(1) and VPAC(2) receptors) are involved in promotion and growth of many human tumours including breast cancer...
  7. ncbi The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics
    Emilie Ceraudo
    Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de recherche Biomedicale Bichat Beaujon, CRB3, Faculte de Medecine Xavier Bichat, 75018, Paris, France
    Mol Endocrinol 22:147-55. 2008
    The neuropeptide vasoactive intestinal peptide (VIP) strongly impacts on human pathophysiology and does so through interaction with class II G protein-coupled receptors...
  8. ncbi Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells
    Beatriz Collado
    Molecular Neuroendocrinology Unit, Department of Biochemistry and Molecular Biology, Alcala University, E 28871 Alcala de Henares, Spain
    Regul Pept 119:69-75. 2004
    Vasoactive intestinal peptide (VIP) upregulates the expression of vascular endothelial cell growth factor (VEGF(189), VEGF(165) and VEGF(121)) mRNAs in human prostate cancer LNCaP cells, as shown by reverse transcriptase-polymerase chain ..
  9. doi Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer
    Ana Valdehita
    Molecular Neuroendocrinology Unit, Department of Biochemistry and Molecular Biology, Alcala University, 28871 Alcala de Henares, Spain
    Peptides 31:2035-45. 2010
    Vasoactive intestinal peptide (VIP) and its receptors (VPACs) are involved in proliferation, survival, and differentiation in human breast cancer cells...
  10. ncbi VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death
    D E Brenneman
    Section on Developmental and Molecular Pharmacology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
    Brain Res 838:27-36. 1999
    Vasoactive intestinal peptide (VIP) and DAPTA (D-ala(1)-peptide T-amide, a gp120-derived octapeptide homologous to VIP) prevent neuronal cell death produced by five variants of HIV-1 (human immunodeficiency virus) envelope protein (gp120)..
  11. ncbi VIP modulates intracellular calcium oscillations in human lymphoblasts
    P A Anton
    MacDonald Research Laboratories, UCLA School of Medicine 90024
    Immunopharmacol Immunotoxicol 15:429-46. 1993
    Vasoactive intestinal polypeptide (VIP) has been shown to stimulate adenylate cyclase in a human lymphoblast cell line (MOLT 4)...
  12. pmc Inhibition of rat colon contractility by prostacyclin (IP-) receptor agonists: involvement of NANC neurotransmission
    Y M Qian
    Department of Pharmacology, Faculty of Medicine, Chinese University of Hong Kong, Shatin, NT
    Br J Pharmacol 115:163-71. 1995
    ..5. Investigation of vasoactive intestinal peptide (VIP) as a potential transmitter showed that its inhibitory action on the colon (IC50 = 50 nM) was partially inhibited ..
  13. pmc The influence of the trigeminal ganglion on carotid blood flow in anaesthetized guinea-pigs
    D T Beattie
    Pharmacology II, Glaxo Research and Development Ltd, Ware, Herts
    Br J Pharmacol 112:262-6. 1994
    ..3. In animals pretreated with guanethidine, intravenous administration of the vasoactive intestinal polypeptide (VIP) receptor antagonist, [p-Cl-D-Phe6,Leu17]-VIP (50 micrograms kg-1) significantly attenuated the increase in carotid ..
  14. pmc Regulation of NANC neural bronchoconstriction in vivo in the guinea-pig: involvement of nitric oxide, vasoactive intestinal peptide and soluble guanylyl cyclase
    Y H Lei
    Department of Thoracic Medicine, National Heart and Lung Institute, London
    Br J Pharmacol 108:228-35. 1993
    ..Vasoactive intestinal peptide (VIP, 10 ig kg-' i.v. infused over min) significantly reduced by 70% the increase in PIP induced by NKA (0.1 ...
  15. pmc Profile of capsaicin-induced mouse ear oedema as neurogenic inflammatory model: comparison with arachidonic acid-induced ear oedema
    H Inoue
    Research Laboratory, Minophagen Pharmaceutical Co, Kanagawa, Japan
    Br J Pharmacol 110:1614-20. 1993
    ..such as rat calcitonin gene-related peptide (CGRP), SP, neurokinin A (NKA), and vasoactive intestinal peptide (VIP), which are released from capsaicin-sensitive neurones, caused ear oedema by intradermal injection...
  16. ncbi Gastrointestinal hormones and the quantitation of spontaneous duodenal motor activity
    M F Tansy
    Temple University Health Sciences Center, Philadelphia, Pennsylvania 19140
    Toxicol Pathol 16:118-22. 1988
    ..These include vasoactive intestinal polypeptide (VIP), gastric inhibitory polypeptide (GIP), motilin, pancreatic polypeptide (PP), substance P, neurotensin, ..
  17. ncbi Vasoactive intestinal peptide stimulates rat adrenal glucocorticoid secretion, through an ACTH receptor-dependent activation of the adenylate cyclase signaling pathway
    G Mazzocchi
    Department of Anatomy, University of Padua, Italy
    Horm Metab Res 30:241-3. 1998
    Vasoactive intestinal peptide (VIP) concentration-dependently enhanced corticosterone and cyclic-AMP release by dispersed rat inner adrenocortical cells...
  18. ncbi Substance P theory: a unique focus on the painful and painless phenomena of cluster headache
    F Sicuteri
    Institute of Internal Medicine and Therapy, IV, University of Florence, Italy
    Headache 30:69-79. 1990
    ..smooth muscle (of the iris in CH); substance P (SP) and allied transmitters such as Vasoactive Intestinal Peptide (VIP) and Calcitonin Gene-Related Peptide (CGRP) are the main agonists of this dual afferent-efferent function; b) ..
  19. pmc GH4ZD10 cells expressing rat 5-HT1A receptors coupled to adenylyl cyclase are a model for the postsynaptic receptors in the rat hippocampus
    C J Fowler
    Department of Neuropharmacology, CNS Preclinical R and D, Astra Arcus AB, , Sweden
    Br J Pharmacol 107:141-5. 1992
    1. Vasoactive intestinal polypeptide (VIP) stimulated adenosine 3':5'-cyclic monophosphate (cyclic AMP) production by cultured GH4ZD10 cells with an EC50 value of about 7 nM...
  20. ncbi [Role of neuropeptides in dermatology]
    I Sanchez-Carpintero
    Departamento de Dermatologia, Clinica Universitaria, Facultad de Medicina, Universidad de Navarra, Pamplona, Espana
    Rev Neurol 25:S222-31. 1997
    ..as substance P (SP), calcitonin gene related peptide (CGRP), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), somatostatin (S), and neurotensin (N). Several NP induce inflammatory response with edema and erythema...
  21. ncbi Modulating effects of sensory and autonomic neuropeptides on murine splenocyte proliferation and cytokine secretion induced by Leishmania major
    A A Ahmed
    Department of Dermatology, Karolinska Hospital, Stockholm, Sweden
    Immunopharmacol Immunotoxicol 21:507-26. 1999
    ..study was undertaken to investigate the possible immunomodulatory role of sensory (SOM, CGRP and SP) and autonomic (VIP and NPY) neuropeptides in a murine model of cutaneous leishmaniasis, using two genetically different inbred mouse ..
  22. pmc Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum
    P Hedlund
    Department of Clinical Pharmacology, Lund University Hospital, Sweden
    Br J Pharmacol 116:2258-66. 1995
    ..polypeptide (PACAP-27 and -38), helospectin (Hel-1 and Hel-2), and vasoactive intestinal polypeptide (VIP), were investigated in isolated preparations of human corpus cavernosum (CC). 2...
  23. ncbi Neuropeptides modulate a murine monocyte/macrophage cell line capacity for phagocytosis and killing of Leishmania major parasites
    A A Ahmed
    Department of Dermatology, Karolinska Hospital, Stockholm, Sweden
    Immunopharmacol Immunotoxicol 23:397-409. 2001
    ..The autonomic neuropeptides vasoactive intestinal peptide (VIP) and neuropeptide Y (NPY) both suppressed the phagocytic and leishmanicidal capacities of macrophages at various ..
  24. pmc Capsaicin-induced relaxation in the rat isolated external urethral sphincter: characterization of the vanilloid receptor and mediation by CGRP
    M Parlani
    Menarini Ricerche Sud, Pharmacology Department, Pomezia, Rome, Italy
    Br J Pharmacol 110:989-94. 1993
    ..3-10 microM), but not by substance P (1 microM), vasoactive intestinal polypeptide (VIP, 1 microM), alpha-beta methylene ATP (10 microM), gamma-aminobutyric acid (GABA, 3 mM) or galanin (1 microM)...
  25. ncbi Comparison of the insulinotropic activity of glucagon-superfamily peptides in rat pancreas perfusion
    S Suzuki
    Department of Internal Medicine, University of Tsukuba, Japan
    Horm Metab Res 24:458-61. 1992
    ..having an amino-terminal histidine and carboxy-terminal isoleucine amide (PHI), vasoactive intestinal polypeptide (VIP), growth hormone releasing factor(1-29)amide (GRF), GRF(1-27)amide and synthetic hybrid-peptides of PHI-GRF, PHI(1-..
  26. pmc Mediators of nonadrenergic, noncholinergic inhibition in the proximal, middle and distal regions of rat colon
    N Suthamnatpong
    Department of Veterinary Pharmacology, College of Agriculture, University of Osaka Prefecture, Sakai, Japan
    Br J Pharmacol 108:348-55. 1993
    ..NANC relaxation of the proximal segments was still evident after desensitization to vasoactive intestinal peptide (VIP)...
  27. ncbi Neuropeptide Y, tyrosine hydroxylase and vasoactive intestinal polypeptide-immunoreactive nerve fibers in the vertebral bodies, discs, dura mater, and spinal ligaments of the rat lumbar spine
    M Ahmed
    Department of Orthopaedics, Karolinska Institute, Stockholm, Sweden
    Spine (Phila Pa 1976) 18:268-73. 1993
    ..peptidergic nerves, represented by immunoreactivity to neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP), and noradrenergic nerves as reflected by tyrosine hydroxylase (TH) immunoreactivity, were identified...
  28. ncbi Pancreatic secretagogues regulate somatostatin binding to acinar cell membranes via two-functionally distinct pathways
    T Matozaki
    Second Department of Internal Medicine, Kobe University School of Medicine, Japan
    Horm Metab Res 20:141-4. 1988
    Pretreatment of pancreatic acini with vasoactive intestinal peptide (VIP) or secretin for 120 min reduced subsequent [125I-Tyr1]somatostatin binding to membranes prepared from these acini, with a maximally reduced binding being 79...
  29. pmc Contribution of ATP and nitric oxide to NANC inhibitory transmission in rat pyloric sphincter
    P Soediono
    Department of Anatomy and Developmental Biology, University College London
    Br J Pharmacol 113:681-6. 1994
    ..7. While abundant vasoactive intestinal polypeptide (VIP)-containing nerve fibres were demonstrated immunohistochemically in the pyloric sphincter, relaxations to VIP (1 nM-..
  30. ncbi Cholecystokinin and vasoactive intestinal peptide in brain and gut of the hypothyroid neonatal rat
    B Zheng
    Solomon A. Berson Research Laboratory, Veterans Administration Medical Center, Bronx, New York
    Horm Metab Res 21:127-31. 1989
    ..the concentrations and contents of immunoreactive cholecystokinin (CCK) and vasoactive intestinal peptide (VIP) in the brain and gut of groups of rats exposed to antithyroid medication from day 16 of gestation...
  31. ncbi Lithium inhibits substance P and vasoactive intestinal peptide-induced relaxations on isolated porcine ophthalmic artery
    M B Vincent
    Department of Neurology, Trondheim University Hospital, Norway
    Headache 32:335-9. 1992
    ..Vasoactive intestinal peptide (VIP), SP, CGRP, capsaicin, and SP+CGRP concentration-response relaxation curves were obtained in the presence and ..
  32. ncbi Neuropharmacologic effects of vibration on the dorsal root ganglion. An animal model
    J Weinstein
    University of Iowa, Spine Treatment and Research Center, Iowa City
    Spine (Phila Pa 1976) 13:521-5. 1988
    ..This investigation was undertaken to validate the hypothesis that substance P and VIP, known to be produced in the dorsal root ganglion cell bodies, will be affected by low frequency vibration...
  33. ncbi Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist
    I Gozes
    Department of Hormone Research, Weizmann Institute of Science, Rehovot, Israel
    Endocrinology 125:2945-9. 1989
    Vasoactive intestinal peptide (VIP) has been suggested as a neurotransmitter mediating penile erection. We now show that VIP can stimulate sexual behavior in rats with reduced masculine potential due to pituitary grafting or castration...
  34. ncbi Modulation of immune function by intestinal neuropeptides
    L P Sirinek
    Department of Pediatrics, Ohio State University, Columbus
    Acta Oncol 30:509-17. 1991
    ..Peptides to be discussed include substance P, somatostatin, vasoactive intestinal peptide (VIP), the opioid peptides leu and met enkephalin, calcitonin gene related peptide (CGRP), neuropeptide Y, and ..
  35. ncbi Prolactin and rapid eye movement sleep regulation
    R Roky
    Department of Physiology and Biophysics, University of Tennessee, Memphis 38163, USA
    Sleep 18:536-42. 1995
    ..Stimulation of endogenous PRL secretion by vasoactive intestinal peptide (VIP) also promotes REMS. Immunoneutralization of blood-borne PRL slightly reduces REMS...
  36. ncbi Vasoactive-intestinal-peptide- and substance-P-immunoreactive nerve fibres in the myenteric plexus of mouse colon during the chronic phase of Trypanosoma cruzi infection
    L B Maifrino
    Instituto Dante Pazzanese de Cardiologia, Brazil
    Ann Trop Med Parasitol 93:49-56. 1999
    The distribution of a tachykinin (substance P) and vasoactive intestinal peptide (VIP) and the number and morphology of the large granular vesicles (LGV) in the myenteric plexus of the colons of mice were investigated...
  37. ncbi Vasoactive intestinal polypeptide induces REM recovery in insomniac forebrain lesioned cats
    M T Pacheco-Cano
    Departamento de Neurociencias, ,
    Sleep 13:297-303. 1990
    ..Recently it has been shown that vasoactive intestinal polypeptide (VIP) may be a specific REM inductor in the parachlorophenylalanine (PCPA) insomniac model...
  38. ncbi Neuropeptide changes in compressed spinal nerve roots
    M Cornefjord
    Department of Orthopaedics, Sahlgren Hospital, University of Gothenburg, Sweden
    Spine (Phila Pa 1976) 20:670-3. 1995
    STUDY DESIGN. Compression-induced changes in the concentration of substance P and VIP (vasoactive intestinal polypeptide), in spinal nerve roots and dorsal root ganglia were studied in an experimental nerve root compression model in pigs...
  39. ncbi Opiate modulation of the stress-induced increase of vasoactive intestinal peptide (VIP) in plasma
    T A Crozier
    Zentrum Anaesthesiologie, , Germany
    Horm Metab Res 20:352-6. 1988
    Vasoactive intestinal peptide (VIP) has a variety of extra-intestinal actions which are typical of the body's reaction to stress, such as lipolysis, glycogenolysis and modulation of anterior pituitary hormone secretion...
  40. pmc Effect of diabetes on relaxations to non-adrenergic, non-cholinergic nerve stimulation in longitudinal muscle of the rat gastric fundus
    K M Jenkinson
    Department of Medical Laboratory Science, Royal Melbourne Institute of Technology, Victoria, Australia
    Br J Pharmacol 116:1551-6. 1995
    ..5. Relaxations to both nitric oxide (NO; 1-30 microM) and vasoactive intestinal polypeptide (VIP; 0...
  41. ncbi Protecting effects of vasoactive intestinal polypeptide on lymphocytes against metal toxicity
    K Nordlind
    Department of Dermatology, Karolinska Hospital, Stockholm, Sweden
    Immunopharmacol Immunotoxicol 14:323-30. 1992
    ..gene-related peptide (CGRP), cholecystokinin (CCK), neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP), were investigated for a potential protective effect on thymocytes after a toxic dose of nickel sulfate, giving an ..
  42. ncbi [Vasoactive intestinal peptide in heart failure]
    P Lucia
    II Clinica Medica, , Roma
    Ital Heart J Suppl 1:679-85. 2000
    ..BACKGROUND: The aim of our study was to investigate the pathophysiological role of the vasoactive intestinal peptide (VIP), a vasodilating neuropeptide with positive inotropic and chronotropic properties, in heart failure...
  43. pmc Functional characterization of the adenosine receptor mediating inhibition of intestinal secretion
    D L Hancock
    School of Pharmacology, Unit of Addictive Drug Research, Victorian College of Pharmacy, Monash University, Parkville, Australia
    Br J Pharmacol 114:152-6. 1995
    ..to anaesthetized rats. Intestinal secretion was then stimulated by i.a. infusion of vasoactive intestinal peptide (VIP, 0...
  44. ncbi Vasoactive intestinal polypeptide and neuropeptide-Y, as possible mediators in laryngeal oedema. An immunofluorescence study
    J Basterra
    Surgical Dpt, Valencia Medical School, Spain
    Acta Otorhinolaryngol Belg 43:99-104. 1989
    ..Vasoactive intestinal polypeptide (VIP) and Neuropeptide-Y (NPY) are of interest because of their association with the autonomic nervous system...
  45. ncbi The pain of discography
    J Weinstein
    Spine Diagnostic and Treatment Center, University of Iowa, Iowa City
    Spine (Phila Pa 1976) 13:1344-8. 1988
    ..another? This study was performed to investigate the changes in Substance P (SP) and Vasoactive-Intestinal Peptide (VIP), found in the dorsal root ganglion, following discography in normal and abnormal canine lumber intervertebral ..
  46. ncbi Direct suppression by beta-mercaptoethanol of the prolactin immunoreactivity within the cultured rat adenohypophyseal cells
    K Nakamura
    Second Department of Physiology, School of Medicine, Iwate Medical University, Japan
    Horm Metab Res 25:603-7. 1993
    ..effects were observed under basal condition, as well as during stimulation with vasoactive intestinal peptide (VIP). The minimum effective doses of ME ranged from 0.0001 to 0.01%...
  47. ncbi Concentrations and distribution of vasoactive intestinal peptide (VIP), peptide histidine isoleucine (PHI) and peptide histidine valine (PHV) in the cerebral cortex and the suprachiasmatic nucleus of the mouse
    J D Mikkelsen
    Institute of Medical Anatomy B, University of Copenhagen, Panum Institute, Denmark
    Brain Res 656:95-107. 1994
    Prepro-vasoactive intestinal peptide (prepro-VIP) is processed to at least three biologically active peptides: VIP, peptide histidine isoleucine (PHI) and an extended PHI, peptide histidine valine (PHV)...
  48. ncbi Vasoactive intestinal peptide stimulates T lymphocytes to release IL-5 in murine schistosomiasis mansoni infection
    R C Mathew
    Department of Internal Medicine, University of Iowa College of Medicine, Iowa City 52242
    J Immunol 148:3572-7. 1992
    ..The granulomas have eosinophils that produce vasoactive intestinal peptide (VIP) and T cells that display VIP receptors...
  49. doi Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells
    Orhan Tansel Korkmaz
    Department of Physiology, Medical Faculty, Eskisehir Osmangazi University, 26480, Eskisehir, Turkey
    J Mol Neurosci 41:278-87. 2010
    ..In a previous study, we found that systemically administered vasoactive intestinal peptide (VIP) was effective at reversing the motor deficits (but not the decline in striatal dopamine levels) in a rat model of ..
  50. ncbi Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart
    Darrell R Sawmiller
    Department of Internal Medicine, University of South Florida Health Science Center, 12901 Bruce B Downs Blvd, MDC 19, Tampa, FL 33612 4799, USA
    Neuropeptides 38:289-97. 2004
    The potency and mechanism of action of vasoactive intestinal peptide (VIP) for producing coronary vasodilation was investigated in the isolated perfused heart of the rat...
  51. ncbi Excitatory actions of vasoactive intestinal peptide on mouse thalamocortical neurons are mediated by VPAC2 receptors
    Sang Hun Lee
    Department of Molecular and Integrative Physiology, University of Illinois, Urbana, IL 61801, USA
    J Neurophysiol 96:858-71. 2006
    ..Vasoactive intestinal peptide (VIP) is a neuropeptide localized within the thalamus and strongly attenuates intrathalamic rhythms via an unidentified ..
  52. pmc Effect of passive sensitization on the mechanical activity of human isolated bronchial smooth muscle induced by substance P, neurokinin A and VIP
    A Ben Jebria
    Laboratoire de Physiologie, , , France
    Br J Pharmacol 109:131-6. 1993
    ..induced by the following neuropeptides substance P (SP), neurokinin A (NKA) and vasoactive intestinal peptide (VIP) was studied both in the absence and in the presence of the neutral endopeptidase (NEP) inhibitor, phosphoramidon...
  53. ncbi Mechanisms of vasoactive intestinal peptide-elicited coronary vasodilation in the isolated perfused rat heart
    Darrell R Sawmiller
    Department of Internal Medicine Cardiology, University of South Florida Health Science Center, Tampa, FL 33612 4799, USA
    Neuropeptides 40:349-55. 2006
    The present study investigated the potential role of vasoactive intestinal peptide (VIP) receptors, VPAC1 and VPAC2, in VIP-elicited coronary vasodilation of the isolated perfused rat heart...
  54. ncbi [Changes of vasoactive intestinal polypeptide and vasoactive intestinal polypeptide receptor 1 in small intestine and liver during macaque development]
    Mei Mei Guo
    Division of Peptides Related with Human Diseases, State Key Laboratory of Biotherapy of Human Diseases, West China Hospital, Sichuan University, Chengdu, China
    Sheng Li Xue Bao 59:163-8. 2007
    The present study was aimed to investigate the changes of vasoactive intestinal polypeptide (VIP) and VIP receptor 1 (VIPR1) in small intestinal and hepatic tissues during macaque development...
  55. doi Involvement of vasoactive intestinal polypeptide in the parasympathetic vasodilatation of the rat masseter muscle
    Takeharu Niioka
    Division of Physiology, Department of Oral Biology, School of Dentistry, Health Sciences University of Hokkaido, Ishikari Tobetsu, Hokkaido 061 0293, Japan
    Arch Oral Biol 54:909-16. 2009
    ..However, the non-cholinergic mechanisms are still unclear. Recently, vasoactive intestinal polypeptide (VIP) was convincingly shown to be involved in the parasympathetic vasodilatation in orofacial areas, such as ..
  56. doi Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells
    Mario Delgado
    Instituto de Parasitologia y Biomedicina Lopez Neyra, CSIC, Granada, Spain
    Arthritis Rheum 58:1010-9. 2008
    Vasoactive intestinal peptide (VIP) has been shown to be one of the endogenous factors involved in the maintenance of immune tolerance. Administration of VIP ameliorates clinical signs in various experimental autoimmune disorders...
  57. ncbi Vasoactive intestinal peptide modulates luteinizing hormone subunit gene expression in the anterior pituitary in female rat
    Alina Gajewska
    Kielanowski Institute of Animal Physiology and Nutrition, Polish Academy of Sciences, Warsaw
    Brain Res Bull 67:319-26. 2005
    The direct monosynaptic pathway which exists between vasoactive intestinal peptide (VIP) and GnRH neurons in the hypothalamic preoptic area provides a neuroanatomical background for the modulatory effects of VIP exerted on GnRH neurons ..
  58. ncbi Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis
    Wei Sun
    Department of Neurology, Baylor College of Medicine, Mail station NB302, One Baylor Plaza, Houston, TX 77030, USA
    Int Immunol 18:1691-700. 2006
    Vasoactive intestinal peptide (VIP) has a unique property of regulating T(h)1 and T(h)2 immunity of CD4+ T cells...
  59. pmc Characterization of the rat vasoactive intestinal polypeptide receptor gene 5' region
    L Pei
    Division of Endocrinology, Cedars Sinai Medical Center UCLA School of Medicine 90048, USA
    Biochem J 308:719-23. 1995
    The broad spectrum of vasoactive intestinal polypeptide (VIP) cellular functions are mediated by high-affinity binding sites...
  60. pmc The role of joint nerves and mast cells in the alteration of vasoactive intestinal peptide (VIP) sensitivity during inflammation progression in rats
    Jason J McDougall
    Department of Physiology and Biophysics, University of Calgary, 3330, Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
    Br J Pharmacol 145:104-13. 2005
    The present study examined the peripheral effects of vasoactive intestinal peptide (VIP) on rat knee joint blood flow during acute and chronic inflammation...
  61. ncbi Effect of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on pancreatic, hepatic and duodenal mucosal bicarbonate secretion in the pig
    Henrik Glad
    Department of Medical Gastroenterology, Odense University Hospital, Odense University, Odense, Denmark
    Digestion 67:56-66. 2003
    ..of pituitary adenylate cyclase-activating polypeptide (PACAP) and the related vasoactive intestinal peptide (VIP) on pancreaticobiliary and duodenal mucosal bicarbonate secretion (DMBS) was studied in anaesthetized pigs...
  62. pmc Vasoactive intestinal polypeptide mediates cholecystokinin-induced relaxation of the sphincter of Oddi
    J W Wiley
    University of Michigan Medical Center, Department of Internal Medicine, Ann Arbor 48109
    J Clin Invest 81:1920-4. 1988
    ..the hypothesis that cholecystokinin (CCK) relaxes the sphincter of Oddi via vasoactive intestinal polypeptide (VIP). Isolated canine sphincter of Oddi were suspended in organ baths under standard conditions...
  63. ncbi Levels of vasoactive intestinal peptide, cholecystokinin and calcitonin gene-related peptide in plasma and jejunum of rats following traumatic brain injury and underlying significance in gastrointestinal dysfunction
    Chun Hua Hang
    Department of Neurosurgery, Jinling Hospital, 305 East Zhongshan Road, Nanjing 210002, Jiangsu Province, China
    World J Gastroenterol 10:875-80. 2004
    ..To study the alterations of brain-gut peptides following traumatic brain injury (TBI) and to explore the underlying significance of these peptides in the complicated gastrointestinal dysfunction...
  64. ncbi Significance of changes of gastrointestinal peptides in blood and ileum of experimental spleen deficiency rats
    Li Sheng Li
    Department of Physiology, Capital University of Medical Sciences, 100054, Beijing, China
    World J Gastroenterol 9:553-6. 2003
    ..To explore the mechanism of spleen deficiency (SD) by studying the relationship of gastro-intestinal peptides level and ileal electro-mechanical activity of SD rats and cold restrain rats...
  65. ncbi Vasoactive intestinal peptide modulates Langerhans cell immune function
    Sreedevi Kodali
    Department of Dermatology, Joan and Sanford I Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    J Immunol 173:6082-8. 2004
    ..The neuropeptide vasoactive intestinal peptide (VIP) has also been found in cutaneous nerves and mRNA, for the VIP receptor vasoactive intestinal peptide receptor type ..
  66. ncbi Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells
    M Lara-Marquez
    Children s Research Institute, Departments of Pediatrics, Molecular Immunology, Virology, and Human Genetics, and Internal Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43205, USA
    J Immunol 166:2522-30. 2001
    Vasoactive intestinal peptide (VIP) has potent antiproliferative and anti-inflammatory functions in the immune system...
  67. ncbi Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes
    M S Rodriguez-Pena
    Departamento de Bioquimica y Biologia Molecular, Universidad de Alcala, Alcala de Henares, Madrid, Spain
    Eur J Pharmacol 208:207-12. 1991
    Vasoactive intestinal peptide (VIP) receptors coupled to activation of adenylate cyclase have been previously identified in seminal vesicle membranes of rat...
  68. ncbi Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary
    Marzia Barberi
    Department of Histology and Medical Embriology, La Sapienza University of Rome, Via A Scarpa, 14, Rome 00161, Italy
    Reproduction 134:281-92. 2007
    Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) positively affect several parameters correlated with the ovulatory process...
  69. ncbi Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate
    R M Solano
    Department of Biochemistry and Molecular Biology, University of Alcala, Alcala de Henares, Spain
    Endocrinology 137:2815-22. 1996
    Vasoactive intestinal peptide (VIP) is an important member of the group of neuropeptides that appears to be involved in the regulation of prostatic growth and function...
  70. ncbi Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies
    Solveig Schulz
    Department of Obstetrics and Gynecology, Otto von Guericke University, Magdeburg, Germany
    Clin Cancer Res 10:8235-42. 2004
    Human tumors frequently overexpress receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP)...
  71. ncbi Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice
    Julia K Voice
    Department of Medicine, University of California Medical Center, San Francisco, CA 94143, USA
    J Immunol 170:308-14. 2003
    Vasoactive intestinal peptide (VIP) and its two G protein-coupled receptors, VPAC1 and VPAC2, are quantitatively prominent and functionally critical in the immune system...
  72. ncbi Effect of vasoactive intestinal peptide on gastric adenocarcinoma
    Guo Hua Li
    Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China
    J Gastroenterol Hepatol 22:1328-35. 2007
    Vasoactive intestinal peptide (VIP) is a gastrointestinal hormone in the secretin-VIP family. It has been reported that VIP affects some tumor growth, and there is a VIP autocrine regulation in some cancers...
  73. ncbi PACAP-(6-38) inhibits the effects of vasoactive intestinal polypeptide, but not PACAP, on the small intestinal circular muscle
    Z Lazar
    Department of Pharmacology and Pharmacotherapy, University of Pecs, Szigeti u 12, H 7643 Pecs, Hungary
    Eur J Pharmacol 431:259-64. 2001
    Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating peptide-(1-38) (PACAP) have been found to stimulate distension-induced peristaltic motility in the guinea-pig isolated small intestine...
  74. pmc Vasoactive intestinal polypeptide can excite gonadotropin-releasing hormone neurons in a manner dependent on estradiol and gated by time of day
    Catherine A Christian
    Neuroscience Graduate Program, Department of Medicine, University of Virginia, Charlottesville, Virginia 22908, USA
    Endocrinology 149:3130-6. 2008
    ..Vasoactive intestinal polypeptide (VIP) may be involved in suprachiasmatic nuclei-GnRH neuron communication...
  75. ncbi VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes
    Lina Akesson
    Section for Molecular Signaling, Department of Cell and Molecular Biology, Biomedical Center C11, Lund University, SE 221 84 Lund, Sweden
    Endocrinology 146:744-50. 2005
    The neuropeptides pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) are structurally and functionally related...
  76. ncbi Functional expression of receptors for calcitonin gene-related peptide, calcitonin, and vasoactive intestinal peptide in the human thymus and thymomas from myasthenia gravis patients
    J Marie
    Institut National de la Sante et de la Recherche Medicale, Unit 482, Signalisation et Fonctions Cellulaires, Applications au Diabète et aux Cancers Digestifs, Hopital Saint Antoine, Paris, France
    J Immunol 162:2103-12. 1999
    The molecular and functional expression of serpentine membrane receptors for vasoactive intestinal peptide (VIP), calcitonin gene-related peptide (CGRP), and calcitonin (CT) were characterized in human thymus and thymomas from myasthenia ..
  77. ncbi Androgens augment vasoactive intestinal peptide- and growth hormone-releasing hormone-stimulated progestin production by rat granulosa cells
    Y D Li
    Department of Pharmacology, College of Medicine, University of Iowa, Iowa City 52242
    Endocrinology 132:584-90. 1993
    Vasoactive intestinal peptide (VIP) has been shown to stimulate steroid production by cultured rat granulosa cells independently of FSH. In the present study, we have examined the modulatory effects of various steroids on this response...
  78. ncbi Effect of fluoxetine on depression-induced changes in the expression of vasoactive intestinal polypeptide and corticotrophin releasing factor in rat duodenum
    Yong Lan Huang
    Department of Mental Health Center, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China
    World J Gastroenterol 13:6060-5. 2007
    To investigate changes in vasoactive intestinal polypeptide (VIP) and corticotrophin releasing factor (CRF) in the plasma and duodenum of chronic stress-induced depressed rats and the effects of fluoxetine hydrochloride (fluoxetine) ..
  79. ncbi Immunohistochemical localization of vasoactive intestinal peptide (VIP) in the circumventricular organs of the rat
    J D Mikkelsen
    Institute of Medical Anatomy, University of Copenhagen, Denmark
    Cell Tissue Res 255:307-13. 1989
    ..immunohistochemical technique was used to investigate the possible presence of vasoactive intestinal peptide (VIP) in the circumventricular organs of the rat...
  80. ncbi Dual actions of S-nitrosylated derivative of vasoactive intestinal peptide as a vasoactive intestinal peptide-like mediator and a nitric oxide carrier
    L Jia
    VAMC, University of California, San Diego School of Medicine, 92161, USA
    Eur J Pharmacol 366:79-86. 1999
    Vasoactive intestinal peptide (VIP) has been postulated as a non-adrenergic non-cholinergic (NANC) transmitter in the relaxation of vascular and non-vascular systems...
  81. pmc Effects of vasoactive intestinal peptide, helodermin and galanin on responses of guinea-pig lung parenchyma to histamine, acetylcholine and leukotriene D4
    D M Conroy
    Department of Pharmacology, Hunterian Institute, Royal College of Surgeons, London
    Br J Pharmacol 104:1012-8. 1991
    1. The effect of vasoactive intestinal peptide (VIP) was studied on the contractile response of guinea-pig lung parenchymal strips (GPP) induced by bronchoconstrictor agonists, such as leukotriene D4 (LTD4), histamine and acetylcholine (..
  82. pmc Effects of vasoactive intestinal polypeptide on antigen-induced bronchoconstriction and thromboxane release in guinea-pig lung
    G Ciabattoni
    Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
    Br J Pharmacol 109:243-50. 1993
    1. Exogenous vasoactive intestinal polypeptide (VIP) infused into the pulmonary artery of isolated and ventilated lungs of guinea-pigs decreased, in a dose-dependent fashion (1.0-10...
  83. ncbi Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis
    Jolanta B Zawilska
    Department of Pharmacodynamics, Medical University of Lodz, 1 Muszynskiego St, 90 151 Lodz, Poland
    Gen Comp Endocrinol 137:187-95. 2004
    Receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in turkey cerebral cortex were characterized using two approaches: (1) in vitro radioreceptor binding of [125I]-VIP, and (2) ..
  84. ncbi Participation of vasoactive intestinal polypeptide in ovarian steroids production during the rat estrous cycle and in the development of estradiol valerate-induced polycystic ovary
    Claudio Parra
    Lab Neurobioquímica, Departamento de Bioquimica y Biologia Molecular, Facultad de Ciencias Quimicas y Farmaceuticas, Universidad de Chile, Santiago, Chile
    Reproduction 133:147-54. 2007
    Vasoactive intestinal polypeptide (VIP) stimulates estradiol and progesterone release from ovarian granulosa cells in vitro...
  85. pmc Regional haemodynamic responses to pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide in conscious rats
    S M Gardiner
    Department of Physiology and Pharmacology, University of Nottingham Medical School, Queen s Medical Centre
    Br J Pharmacol 111:589-97. 1994
    ..peptides, pituitary adenylate cyclase-activating peptide (1-27) (PACAP27) and vasoactive intestinal polypeptide (VIP) were assessed by giving 20 min infusions (1...
  86. pmc Interplay between nitric oxide and vasoactive intestinal polypeptide in inducing fluid secretion in rat jejunum
    F H Mourad
    Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Lebanon
    J Physiol 550:863-71. 2003
    Nitric oxide (NO) and vasoactive intestinal polypeptide (VIP) interact in the regulation of neuromuscular function in the gut. They are also potent intestinal secretogogues that coexist in the enteric nervous system...
  87. ncbi Role of the vasoactive intestinal peptide in a neuroendocrine regulation of the adrenal cortex
    M Ehrhart-Bornstein
    Institute for Medical Physiology C, University of Copenhagen, Denmark
    Neuroendocrinology 54:623-8. 1991
    ..nerve supply, we measured the release of cortisol and aldosterone and of the vasoactive intestinal peptide (VIP) after electrical stimulation of the splanchnic nerves...
  88. ncbi Ganglion cells immunoreactive for catecholamine-synthesizing enzymes, neuropeptide Y and vasoactive intestinal polypeptide in the rat adrenal gland
    Y Oomori
    Department of Anatomy, Asahikawa Medical College, Japan
    Cell Tissue Res 275:201-13. 1994
    ..DBH), phenylethanolamine N-methyltransferase (PNMT), neuropeptide Y (NPY) and vasoactive intestinal polypeptide (VIP) immunoreactivities, and acetylcholinesterase (AChE) activity was demonstrated in rat adrenal glands...
  89. ncbi Influence of 4-day long treatment with vasoactive intestinal peptide on ultrastructure and function of the rat pinealocytes in organ culture
    Marcin Nowicki
    Department of Histology and Embryology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Olsztyn, Poland
    Folia Histochem Cytobiol 40:9-16. 2002
    Vasoactive intestinal peptide (VIP) is one of neuropeptides involved in the regulation of the pineal gland function. The acute treatment of rat pinealocytes with VIP caused changes in their biochemical parameters...
  90. ncbi Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate
    P J R Shah
    Institute of Urology and Nephrology, London, UK
    Curr Med Res Opin 23:2577-83. 2007
    To compare two injectable treatments, alprostadil 5-20 microg powder for injection and a combination of vasoactive intestinal polypeptide (VIP) and phentolamine in patients with erectile dysfunction (ED).
  91. ncbi [Vasoactive intestinal peptide expression and its clinical significance in gastric adenocarcinoma]
    Hui Chen
    Department of Digestion Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 22:452-4. 2008
    To investigate the expression of vasoactive intestinal peptide (VIP) in gastric adenocarcinoma, and to evaluate the correlation of VIP level with clinical pathologic parameters.
  92. ncbi Cross-talk between cellular signaling pathways activated by substance P and vasoactive intestinal peptide in rat lactotroph-enriched pituitary cell cultures
    S E Mau
    Department of Medical Physiology, University of Copenhagen, Denmark
    Endocrinology 138:1704-11. 1997
    ..C (PKC)/inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) messenger systems probed by vasoactive intestinal peptide (VIP) and substance P (SP), respectively, in rat pituitary cell cultures enriched in lactotrophs...
  93. ncbi Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex
    Jolanta B Zawilska
    Department of Pharmacodynamics, Medical University of Łódź, Muszynskiego 1, PL 90 151 Łódź, Poland
    Pol J Pharmacol 56:203-11. 2004
    Receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the goose cerebral cortex were characterized using two approaches: (1) in vitro radioreceptor binding of [(125)I]-VIP, ..
  94. ncbi Experimental lumbar radiculopathy. Immunohistochemical and quantitative demonstrations of pain induced by lumbar nerve root irritation of the rat
    M Kawakami
    Department of Orthopedic Surgery, Wakayama Medical College, Japan
    Spine (Phila Pa 1976) 19:1780-94. 1994
    ..a consistent trend toward baseline and return to baseline by 12 weeks; significantly greater and highly increased VIP concentrations in the dorsal root ganglia 2 weeks postoperatively (P < ...
  95. pmc Neural, hormonal, and paracrine regulation of gastrin and acid secretion
    M L Schubert
    Department of Medicine, Medical College of Virginia, Richmond 23298-0711
    Yale J Biol Med 65:553-60; discussion 621-3. 1992
    ..The effector neurons comprise cholinergic neurons and two types of non-cholinergic neurons: bombesin/GRP and VIP neurons...
  96. ncbi Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours?
    J Shamash
    Department of Medical Oncology, School of Medicine and Dentistry, St Bartholomew s and Royal London Hospitals, Queen Mary and Westfield College, Smithfield, UK
    Acta Oncol 39:857-63. 2000
    ..Initially, HDCT was given as consolidation of third line VIP (etoposide/ifosfamide and cisplatin), following failure of a weekly cisplatin regimen...
  97. ncbi Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management
    A I Vinik
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109
    Acta Oncol 28:389-402. 1989
    ..In individual instances the tumor may even infarct, leading to spontaneous cure. Tumors secreting PP, ACTH and calcitonin may be particularly resistant to treatment, whereas VIP secreting tumors appear to be sensitive.
  98. doi Vasoactive intestinal peptide produces long-lasting changes in neural activity in the suprachiasmatic nucleus
    Takashi Kudo
    Laboratory of Circadian and Sleep Medicine, Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, CA 90024, USA
    J Neurophysiol 110:1097-106. 2013
    The neuropeptide vasoactive intestinal peptide (VIP) is expressed at high levels in the neurons of the suprachiasmatic nucleus (SCN)...
  99. pmc Two tyrosine residues in the first transmembrane helix of the human vasoactive intestinal peptide receptors play a role in supporting the active conformation
    J Perret
    Department of Biochemistry and Nutrition, School of Medicine, Universite Libre de Bruxelles, Bat G E, CP 611, 808 Route de Lennik, B 1070 Brussels, Belgium
    Br J Pharmacol 136:1042-8. 2002
    1: We investigated the human vasoactive intestinal polypeptide (VIP) receptors VPAC(1) and VPAC(2) mutated at conserved tyrosine residues in the first transmembrane helix (VPAC(1) receptor Y146A and Y150A and VPAC(2) receptor Y130A and ..
  100. pmc Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the cutaneous vasculature of humans
    Lee Ann T Bennett
    Department of Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    J Physiol 552:223-32. 2003
    ..We tested whether AVD is a redundant system in which ACh and vasoactive intestinal polypeptide (VIP) are co-released from cholinergic nerves...
  101. pmc Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor
    Ingrid Nachtergael
    Department of Biochemistry and Nutrition, School of Medicine, Universite Libre de Bruxelles, Bat G E, CP 611, 808 Route de Lennik, B 1070 Bruxelles, Belgium
    Biochem J 370:1003-9. 2003
    We developed previously VPAC(1) [vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP) receptor]>VPAC(2) receptor selective ligands...

Research Grants65

  1. Phospholipid Nanocarriers Improve Chemotherapy by Targeted Drug Delivery
    Hayat Onyuksel; Fiscal Year: 2009
    ..the attributes of sterically stabilized mixed micelles (SSMM) with surface-grafted vasoactive intestinal peptide (VIP). SSMM are composed of a polyethylene glycol (PEG) conjugated phospholipid and phosphatidylcholine...
  2. Phospholipid Nanocarriers Improve Chemotherapy by Targeted Drug Delivery
    Hayat Onyuksel; Fiscal Year: 2010
    ..the attributes of sterically stabilized mixed micelles (SSMM) with surface-grafted vasoactive intestinal peptide (VIP). SSMM are composed of a polyethylene glycol (PEG) conjugated phospholipid and phosphatidylcholine...
  3. Phospholipid Nanocarriers Improve Chemotherapy by Targeted Drug Delivery
    Hayat Onyuksel; Fiscal Year: 2007
    ..the attributes of sterically stabilized mixed micelles (SSMM) with surface-grafted vasoactive intestinal peptide (VIP). SSMM are composed of a polyethylene glycol (PEG) conjugated phospholipid and phosphatidylcholine...
  4. NEUROCHEMISTRY OF GESTATION-PRODUCED ANALGESIA
    ALAN GINTZLER; Fiscal Year: 2007
    ..facilitation of enk release by DOR is triggered by increased release of spinal vasoactive intestinal polypeptide (VIP) from varicosities that appose Dyn neurons...
  5. NEUROCHEMISTRY OF GESTATION-PRODUCED ANALGESIA
    Alan R Gintzler; Fiscal Year: 2010
    ..facilitation of enk release by DOR is triggered by increased release of spinal vasoactive intestinal polypeptide (VIP) from varicosities that appose Dyn neurons...
  6. REGULATION OF IMMUNE CELL APOPTOSIS BY NEUROPEPTIDES
    Doina Ganea; Fiscal Year: 2003
    ..The vasoactive intestinal peptide (VIP) and the related neuropeptide the pituitary adenylate cyclase activating polypeptide (PACAP) are present in the ..
  7. NEUROANATOMY AND MOLECULAR BIOLOGY OF AIRWAY NEURONS
    RICHARD DEY; Fiscal Year: 1993
    ..Airway neurons synthesize and release mediators such as vasoactive intestinal peptide (VIP) and acetylcholine (ACh) which have potent effect in the airways and are involved in mechanisms regulating the ..
  8. 8th International Symposium for VIP, PACAP & Related Peptides
    Victor May; Fiscal Year: 2007
    The 8th International Symposium on VIP, PACAP, and Related Peptides is planned for September 3 - 8, 2007 at The Equinox Spa and Resort in Manchester, Vermont...
  9. Bronchodilation & Anti-Inflammatory Response by VIP
    ANTHONY SZEMA; Fiscal Year: 2007
    ..more effective means of their modulation or prevention, using the neuropeptide vasoactive intestinal peptide (VIP) as a prototype test drug...